Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2026

Segment Reporting

Schedule of certain segment information

The following table includes certain segment information for the periods presented (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Grant and award revenue	$	2,510	$	2,169	$	3,299	$	2,660
Operating expenses
Research and development expenses:
AP-PA02: Non-Cystic Fibrosis Bronchiectasis		16		152		(10)		(288)
AP-PA02: Cystic Fibrosis		8		14		8		25
AP-SA02: Bacteremia		426		1,011		541		1,663
AP-SA02: Prosthetic Joint Infection		-		1		-		2
Expenses not allocated by projects		839		592		1,733		1,112
Total external research and development expenses		1,289		1,770		2,272		2,514
Research and development personnel expenses		3,535		2,293		6,160		4,606
Other research and development expenses		2,762		2,331		5,265		4,703
Total research and development expenses		7,586		6,394		13,697		11,823
General and administrative expenses:
General and administrative personnel expenses		3,045		1,191		4,507		2,592
Other general and administrative expenses		2,191		1,428		4,192		3,280
Total general and administrative expenses		5,236		2,619		8,699		5,872
Total operating expenses		12,822		9,013		22,396		17,695
Operating loss		(10,312)		(6,844)		(19,097)		(15,035)
Other income (expense), net		84,453		(9,451)		(22,108)		(7,791)
Net income (loss)	$	74,141	$	(16,295)	$	(41,205)	$	(22,826)